Meshimakobu

Metadata

Regulatory Status

South Korea

• Pharmaceutical approval: Mesima, a polysaccharide extract from P. linteus mycelial culture produced by submerged liquid fermentation, is an approved pharmaceutical in South Korea for cancer adjunctive immunotherapy. This makes P. linteus one of only a handful of medicinal mushrooms worldwide to achieve formal pharmaceutical status, alongside Turkey Tail PSK (Japan) and Shiitake lentinan (Japan).
• Clinical basis: The Mesima approval was supported by preclinical data demonstrating macrophage, NK cell, and dendritic cell activation, along with controlled clinical studies showing immune parameter enhancement in cancer patients receiving chemotherapy.
• Traditional medicine: Sang Hwang is one of the most revered medicinal mushrooms in Korean traditional medicine (Hanbang). Wild-harvested fruiting bodies from mulberry and other hardwood trees have historically commanded extremely high prices, with specimens occasionally valued at thousands of dollars per kilogram.
• Market significance: South Korea is the primary global market for P. linteus pharmaceutical and supplement products.

Japan

• Historical significance: The common Japanese name “Meshimakobu” refers to Meshima Island (Women’s Island) in Nagasaki Prefecture, where the mushroom was historically collected. The landmark Ikekawa et al. (1968) study that catalyzed modern medicinal mushroom research screened P. linteus against sarcoma 180 in mice, finding a 96.7% tumor inhibition rate — one of the highest among all mushroom species tested.
• Pharmaceutical status: No specific pharmaceutical approval in Japan, though it is available as a health food supplement. Japanese researchers have contributed substantially to taxonomic revision and pharmacological characterization of the species.

China

• Traditional use: Known as Song Gen in traditional Chinese medicine, used for bleeding, amenorrhea, and as a general tonic. The name “Sang Huang” has historically been applied broadly across the Phellinus/Sanghuangporus complex, creating nomenclature confusion (see Taxonomic Note below).
• Pharmacopoeia status: Not listed in the Chinese Pharmacopoeia (2020 edition) as an official monograph entry.

European Union

• Novel Food: Phellinus linteus extracts have not received formal Novel Food authorization under Regulation (EU) 2015/2283. No EMA/HMPC monograph or assessment report exists.

United States

• Dietary supplement: Available under DSHEA. Products include fruiting body extracts, mycelium powders, and polysaccharide-standardized preparations. No FDA GRAS determination.

Taxonomic Note: Phellinus linteus, Meshima, and Sang Huang

The taxonomy of the “Sang Hwang” / “Sang Huang” / “Meshima” complex has been a persistent source of confusion in the medicinal mushroom literature. Clarification of the key species is essential for interpreting the evidence base:

• Phellinus linteus (Berk. & M.A. Curtis) Teng — the subject of this monograph — is now reclassified as Tropicoporus linteus by Zhou & Dai (2012). It grows on a variety of hardwood trees and is the species used to produce the Korean pharmaceutical Mesima. The majority of pharmacological research labeled “Phellinus linteus” or “Sang Hwang” in the Korean and Japanese literature refers to this species.

• Phellinus igniarius (L.) Quel. — traditionally called Meshima in Japanese and some Western references — is a distinct species within the Hymenochaetaceae. It is covered in the separate Meshima monograph on this site. While it shares some pharmacological features with P. linteus (beta-glucan immunostimulation, melanin content), its specific bioactive profile and clinical data differ.

• Sanghuangporus sanghuang (Sheng H. Wu, T. Hatt. & Y.C. Dai) — the “true” Sang Huang in the strict Chinese botanical sense — is a mulberry-tree-specific species reclassified into the genus Sanghuangporus by Wu et al. (2012). It is covered in the separate Sang Huang monograph.

Many older studies, particularly those from the 1990s and 2000s, used the names “Phellinus linteus,” “Sang Hwang,” and “Sang Huang” interchangeably without molecular confirmation of species identity. When evaluating evidence, readers should note that studies from Korean research groups generally used P. linteus sensu stricto (or closely related material), while some Chinese studies may have used S. sanghuang or other species within the complex. This monograph focuses on research that can be reasonably attributed to P. linteus / T. linteus.

Conditions & Indications

Primary Indications (Moderate Evidence)

Immune Modulation and Cancer Adjunctive Therapy

This is the best-supported indication for P. linteus and the basis for its pharmaceutical approval in South Korea. Mesima (mycelial polysaccharide extract) activates innate immune cells — macrophages, NK cells, and dendritic cells — through pattern recognition receptors, enhancing antitumor immune surveillance. Cho et al. (2010) reported that P. linteus mycelial extract improved NK cell activity, CD3+/CD4+ T-cell ratios, and quality of life scores in 68 gastric cancer patients receiving chemotherapy, compared with chemotherapy alone. Multiple Korean clinical studies have consistently demonstrated immune parameter enhancement in oncology patients receiving Mesima alongside conventional treatment. The immune-stimulatory effect is mediated primarily through beta-glucan activation of Dectin-1, TLR-2, and complement receptor 3 (CR3), with downstream NF-kB and MAPK signaling driving cytokine production and immune cell maturation.

Immunostimulation in Immunocompromised States

Beta-glucan polysaccharides from P. linteus enhance innate immune function through multiple receptor systems. Kim et al. (1996) demonstrated that polysaccharide fractions stimulated both humoral and cell-mediated immunity in mice, enhancing splenocyte proliferation, NK cell cytotoxicity, and macrophage phagocytic activity. The acidic polysaccharide fraction (PL-fraction) from mycelial culture broth, which forms the basis of Mesima, is the most extensively characterized immunostimulatory preparation.

Secondary Indications (Preliminary Evidence)

Anti-allergic and Anti-inflammatory Activity

Hispolon and polysaccharide fractions demonstrate anti-allergic effects through inhibition of IgE-mediated mast cell degranulation and suppression of Th2 cytokine production (IL-4, IL-5, IL-13). Choi et al. (2006) showed that P. linteus water extract inhibited anaphylaxis-like reactions and mast cell activation in a mouse model. This dual immunomodulatory profile — stimulating Th1 antitumor immunity while suppressing Th2 allergic responses — is pharmacologically distinctive among medicinal mushrooms.

Hepatoprotection

P. linteus extracts demonstrate liver-protective effects in animal models. Shon et al. (2003) showed that hot-water extract exhibited significant antioxidant and free radical scavenging activity, providing a mechanistic basis for hepatoprotective effects. Kim et al. (2004) demonstrated anti-inflammatory activity in an n-BuOH subfraction that could contribute to liver protection.

Emerging/Preclinical Indications

Direct Antitumor Activity

Hispolon demonstrates direct cytotoxicity against multiple cancer cell lines in vitro, including breast (MCF-7), prostate (LNCaP, DU145), gastric, and hepatocellular carcinoma. Mechanisms include apoptosis induction through caspase-3, -8, and -9 activation, cell cycle arrest at G2/M phase, and NF-kB inhibition. Chen et al. (2008) characterized hispolon’s proapoptotic mechanisms in gastric cancer cells through ROS-mediated mitochondrial pathway. Lu et al. (2009) demonstrated hispolon-induced apoptosis in breast and bladder cancer cells via MDM2-recruited ERK1/2 activity. Clinical translation of these direct antitumor effects remains unestablished.

Anti-angiogenic Effects

Polysaccharide fractions inhibit VEGF-induced angiogenesis in preclinical models. Lee et al. (2010) demonstrated suppression of angiogenesis through downregulation of VEGF and MMP-9 expression. Song et al. (2011) showed that protein-bound polysaccharide from P. linteus inhibited tumor growth, angiogenesis, and tumor-associated macrophage infiltration in mice.

Chemosensitization

Collins et al. (2006) demonstrated that P. linteus extract sensitized prostate cancer cells to doxorubicin-induced apoptosis through NF-kB suppression. Tsuji et al. (2010) confirmed these chemosensitizing effects in an athymic nude mouse xenograft model, where the combination of P. linteus extract and doxorubicin produced significantly greater tumor regression than either agent alone. Sliva et al. (2008) showed inhibition of AKT signaling in breast cancer cells, suppressing growth, angiogenesis, and invasive behavior. These findings suggest potential as a chemotherapy adjuvant, though human studies are needed.

Antidiabetic Activity

Preclinical evidence suggests P. linteus extracts may improve insulin sensitivity and reduce blood glucose through enhanced GLUT-4 translocation and improved beta-cell function in diabetic animal models. Clinical translation remains unestablished.

Mechanism of Action

1. Acidic Polysaccharide Activation of Innate Immunity

Phellinus linteus produces a distinctive profile of acidic polysaccharides, including beta-1,3/1,6-D-glucans with unique branching patterns and heteropolysaccharides containing glucose, galactose, mannose, and xylose. These polysaccharides are recognized by pattern recognition receptors on innate immune cells, principally Dectin-1 (CLEC7A) on macrophages and dendritic cells, TLR-2 on monocytes, and complement receptor 3 (CR3) on NK cells and neutrophils. Receptor engagement triggers NF-kB and MAPK downstream signaling cascades, resulting in enhanced phagocytic activity, pro-inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6, IL-12), augmented NK cell cytotoxicity, and dendritic cell maturation. Kim et al. (2003) demonstrated that the acidic polysaccharide fraction induces nitric oxide and pro-inflammatory cytokine production in murine macrophages through a MyD88-dependent signaling pathway.

The PL-fraction from mycelial culture broth — the active ingredient of the Korean pharmaceutical Mesima — is produced by submerged liquid fermentation, which generates a polysaccharide profile optimized for immunostimulatory activity. This production method is distinct from traditional fruiting body cultivation and yields material with different molecular weight distributions and branching patterns.

2. Hispolon-Mediated Antitumor and Anti-inflammatory Activity

Hispolon (6-(3,4-dihydroxyphenyl)-4-hydroxy-2H-pyran-2-one) is a polyphenolic compound of the styrylpyrone class that represents a key pharmacological differentiator of P. linteus from other medicinal mushrooms. Hispolon exerts multiple mechanisms of antitumor activity:

• Apoptosis induction: Activation of intrinsic (mitochondrial) apoptosis pathway through caspase-3, -8, and -9 activation, cytochrome c release, and downregulation of anti-apoptotic Bcl-2 family proteins. Chen et al. (2008) demonstrated ROS-mediated mitochondrial apoptosis in gastric cancer cells.
• NF-kB inhibition: Suppression of constitutive and inducible NF-kB activation and nuclear translocation, reducing expression of anti-apoptotic proteins (Bcl-xL, survivin) and pro-inflammatory mediators (COX-2, iNOS). This mechanism underlies both antitumor and anti-inflammatory effects.
• Cell cycle arrest: Induction of G2/M cell cycle arrest through modulation of cyclin B1, cdc2, and cyclin-dependent kinase activity.
• ERK1/2 pathway modulation: Lu et al. (2009) demonstrated hispolon induces apoptosis via MDM2-recruited ERK1/2 activity, representing a mechanistically distinct pathway from conventional cytotoxic agents.

3. Selective Th1/Th2 Immunomodulation

In contrast to its immunostimulatory effects on innate immunity and Th1 responses, P. linteus selectively suppresses Th2-mediated allergic responses. Polysaccharide and polyphenolic fractions inhibit IgE-mediated mast cell degranulation, suppress eosinophil infiltration, and reduce Th2 cytokine production (IL-4, IL-5, IL-13) while simultaneously enhancing Th1 cytokines (IFN-gamma, IL-2, IL-12). This selective immunomodulation — stimulating Th1 while suppressing Th2 — is pharmacologically distinctive among medicinal mushrooms and has implications for patients with concurrent immune deficiency and atopic conditions.

4. Interfungin Proteoglycan Activity

P. linteus produces immunomodulatory proteoglycans, including interfungins A, that activate immune cells through mechanisms complementary to beta-glucan receptor signaling. These proteoglycans enhance T-cell proliferation and promote Th1-type cytokine responses, contributing to the overall immunostimulatory profile. Kim et al. (2003b) demonstrated that oral administration of proteoglycan from P. linteus was effective in prevention and treatment of collagen-induced arthritis in mice, suggesting immunomodulatory capacity beyond simple immunostimulation.

Key Active Compounds

Pharmacological Note

Phellinus linteus is pharmacologically distinguished from most other major medicinal mushrooms by two key features: (1) hispolon and related styrylpyrone compounds provide direct cytotoxic and anti-inflammatory activity that complements the immunomodulatory beta-glucan polysaccharides, and (2) the selective Th1-enhancing/Th2-suppressing immunomodulatory profile makes it potentially useful in conditions involving both immune deficiency and immune dysregulation. Dual extraction (hot water + ethanol) of fruiting body material captures the broadest bioactive spectrum, while the Mesima pharmaceutical represents a polysaccharide-optimized mycelial preparation. These are pharmacologically distinct products and should not be considered interchangeable.

Clinical Evidence Summary

Clinical evidence for Phellinus linteus is moderate in quality, concentrated primarily in Korean oncology settings. It is one of the better-studied medicinal mushrooms in terms of clinical application, though the evidence base remains limited by sample size, geographic concentration, and absence of large-scale international trials.

Key Clinical Studies

Evidence from the Korean Mesima Program

• Preclinical package: Extensive in vitro and in vivo studies demonstrating activation of macrophages, NK cells, and dendritic cells; inhibition of tumor growth in multiple murine tumor models (sarcoma 180, Lewis lung carcinoma, B16 melanoma); enhancement of chemotherapy efficacy; anti-metastatic activity.
• Clinical studies: Korean clinical investigations supporting pharmaceutical approval demonstrated immune enhancement in cancer patients, including improved NK cell activity, enhanced T-cell function, and better tolerance of chemotherapy. The Cho et al. (2010) study is the most widely cited in English-language literature.
• Post-marketing experience: Mesima has accumulated over two decades of clinical experience in Korean oncology practice since its pharmaceutical approval, primarily as adjunctive immunotherapy in combination with conventional cancer treatment.

Evidence Limitations

• No large-scale, multicenter, double-blind, placebo-controlled Phase III RCTs published in English-language peer-reviewed journals.
• Most clinical data originates from Korean research groups, and some supporting studies for the Mesima approval are published only in Korean.
• Clinical studies supporting the Mesima approval have not been fully reproduced by independent research groups outside South Korea.
• Mesima uses a specific mycelial culture extract produced by submerged liquid fermentation; supplement-grade products may not be pharmacologically equivalent.
• Published clinical study sample sizes are small to moderate (n=30-68).
• Taxonomic confusion within the Phellinus complex means some studies attributed to “P. linteus” may have used different species.
• The strongest evidence (hispolon-mediated antitumor effects, anti-angiogenesis, chemosensitization) remains entirely preclinical; clinical translation is unestablished.
• The Ikekawa et al. (1968) landmark finding of 96.7% tumor inhibition was in a sarcoma 180 mouse model, which, while historically important, has limited direct translatability to human oncology.

Safety Profile

General Assessment

Phellinus linteus has been consumed in Korean, Japanese, and Chinese traditional medicine for centuries and is generally well-tolerated at standard doses. Clinical studies and the Mesima pharmaceutical program have reported no serious adverse events attributable to P. linteus supplementation. The Mesima post-marketing safety record over two decades supports general tolerability.

Contraindications

• Autoimmune conditions: Immunostimulatory beta-glucan polysaccharides could theoretically exacerbate autoimmune disease activity. Use with caution in patients with systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, or inflammatory bowel disease.
• Organ transplant recipients: Immunostimulatory effects may counteract immunosuppressive therapy. Contraindicated unless under direct specialist supervision.
• Pre-surgical: Discontinue at least 2 weeks before scheduled surgery as a precautionary measure.

Drug Interactions

No clinically documented drug interactions have been reported in human studies or post-marketing surveillance for Mesima. Theoretical considerations based on preclinical data include:

• Immunosuppressants (cyclosporine, tacrolimus, mycophenolate, corticosteroids): Immune-stimulating beta-glucan activity may counteract immunosuppressive therapy. This is the most clinically significant theoretical concern.
• Chemotherapy agents: In its approved Korean indication, Mesima is designed to be used alongside chemotherapy. Korean studies report safety and potential synergy rather than interference, but this should only occur under oncologist supervision.
• Checkpoint inhibitor immunotherapy: Theoretical concern for additive immune stimulation. No clinical interaction data exists.
• Anticoagulants and antiplatelets: Limited preclinical evidence of mild antiplatelet effects. Clinical significance unknown.
• Antidiabetic agents: Preclinical data suggests possible blood glucose lowering. Monitor blood glucose if combining.

Side Effects

• Common: Generally very well-tolerated. Mild gastrointestinal symptoms (nausea, bloating, loose stools) reported occasionally.
• Uncommon: Allergic reactions in individuals sensitive to mushrooms.
• Rare: No serious adverse events reported in published clinical studies or Mesima post-marketing surveillance.

Toxicology

• Acute oral toxicity studies in animals have not identified significant toxicity at doses well above therapeutic range.
• The Mesima pharmaceutical program included standard preclinical safety assessments required for pharmaceutical approval in South Korea.
• Unlike chaga, P. linteus does not contain high concentrations of oxalic acid and does not carry oxalate nephropathy risk.

Pregnancy and Lactation

• Category: Unknown — insufficient data. No controlled human studies in pregnant or lactating women. Avoid during pregnancy and lactation until safety is established.

Clinical Dosage

Mesima (Korean Pharmaceutical Extract)

• Standard dose: 1.5-3 g/day of Mesima (dried mycelial culture polysaccharide extract) in divided doses
• Production method: Submerged liquid fermentation of P. linteus mycelium, producing a polysaccharide-enriched extract
• Important: Mesima is a specific pharmaceutical product with defined manufacturing specifications; supplement-grade P. linteus products may not be pharmacologically equivalent

Hot-Water Extract (Fruiting Body)

• Standard dose: 1-3 g/day of hot-water extracted fruiting body powder, ideally standardized to polysaccharide content
• Preparation: Traditional decoction involves simmering 5-10 g of dried fruiting body in water for 2-3 hours
• Note: Fruiting body extracts provide hispolon and melanins in addition to polysaccharides, offering a broader bioactive profile than mycelial preparations

Dual-Extract Tincture (Water + Ethanol)

• Standard dose: 2-4 mL of 1:5 dual-extract tincture, two to three times daily
• Captures both water-soluble polysaccharides and alcohol-soluble hispolon/phenolic compounds
• Recommended for the broadest bioactive spectrum from fruiting body material

Dried Fruiting Body Powder

• Standard dose: 1-3 g/day in capsule form
• Note: Wild-harvested fruiting bodies are extremely rare and expensive; most commercial products use cultivated material. Unextracted powder has lower bioavailability than extracted preparations.

Quality Considerations

Wild-harvested P. linteus fruiting bodies are scarce and frequently adulterated or misidentified due to the taxonomic complexity of the Phellinus complex. Consumers and practitioners should verify species identity (ideally by molecular authentication) and choose products from suppliers that provide third-party testing for polysaccharide content and species confirmation.

Sources

• Ikekawa T, Nakanishi M, Uehara N, Chihara G, Fukuoka F. Antitumor action of some basidiomycetes, especially Phellinus linteus. Gann. 1968;59(2):155-157
• Kim GY, Oh YH, Park YM. Acidic polysaccharide isolated from Phellinus linteus induces nitric oxide and proinflammatory cytokine production in murine macrophages. J Ethnopharmacol. 2003;88(1):109-116
• Kim GY, Kim SH, Hwang SY, et al. Oral administration of proteoglycan isolated from Phellinus linteus in the prevention and treatment of collagen-induced arthritis in mice. Biol Pharm Bull. 2003;26(6):823-831
• Kim SH, Song YS, Kim SK, Kim BC, Lim CJ, Park EH. Anti-inflammatory and related pharmacological activities of the n-BuOH subfraction of mushroom Phellinus linteus. J Ethnopharmacol. 2004;93(1):141-146
• Kim HM, Han SB, Oh GT, et al. Stimulation of humoral and cell mediated immunity by polysaccharide from mushroom Phellinus linteus. Int J Immunopharmacol. 1996;18(5):295-303
• Chen W, Zhao Z, Li L, et al. Hispolon induces apoptosis in human gastric cancer cells through a ROS-mediated mitochondrial pathway. Free Radic Biol Med. 2008;45(1):60-72
• Lu TL, Huang GJ, Lu TJ, et al. Hispolon from Phellinus linteus has antiproliferative effects via MDM2-recruited ERK1/2 activity in breast and bladder cancer cells. Food Chem Toxicol. 2009;47(8):2013-2021
• Choi YH, Yan GH, Chai OH, et al. Inhibition of anaphylaxis-like reaction and mast cell activation by water extract from the fruiting body of Phellinus linteus. Biol Pharm Bull. 2006;29(7):1360-1365
• Lee YS, Kim YH, Shin EK, et al. Anti-angiogenic activity of methanol extract of Phellinus linteus and its fractions. J Ethnopharmacol. 2010;131(1):56-62
• Song KS, Li G, Kim JS, et al. Protein-bound polysaccharide from Phellinus linteus inhibits tumor growth, angiogenesis, and tumor-associated macrophage in mice. BMC Cancer. 2011;11:109
• Shon MY, Kim TH, Sung NJ. Antioxidants and free radical scavenging activity of Phellinus linteus (Berry & Curtis) Teng (Hymenochaetaceae) extracts. Food Chem. 2003;82(4):593-597
• Collins L, Zhu T, Guo J, Bhatt AP, Slivova V, Sliva D. Phellinus linteus sensitizes apoptosis induced by doxorubicin in prostate cancer. Br J Cancer. 2006;95(2):282-288
• Tsuji T, Du W, Bhatt AP, et al. Phellinus linteus extract sensitizes advanced prostate cancer cells to apoptosis in athymic nude mice. PLoS One. 2010;5(3):e9885
• Sliva D, Jedinak A, Kawasaki J, Harvey K, Slivova V. Phellinus linteus suppresses growth, angiogenesis and invasive behaviour of breast cancer cells through the inhibition of AKT signalling. Br J Cancer. 2008;98(8):1348-1356
• Lee IK, Yun BS. Styrylpyrone-class compounds from medicinal fungi Phellinus and Inonotus spp., and their medicinal importance. J Antibiot (Tokyo). 2011;64(5):349-359
• Zhu T, Kim SH, Chen CY. A medicinal mushroom: Phellinus linteus. Curr Med Chem. 2008;15(13):1330-1335
• Chen H, Tian T, Miao H, Zhao YY. Traditional uses, fermentation, phytochemistry and pharmacology of Phellinus linteus: A review. Fitoterapia. 2016;113:6-26
• Zhou LW, Ghobad-Nejhad M, Tian XM, et al. Current status of ‘Sanghuang’ as a group of medicinal mushrooms and their species diversity. Fungal Divers. 2020;101:127-155
• Wu SH, Dai YC, Hattori T, et al. Species clarification for the medicinally valuable ‘sanghuang’ mushroom. Bot Stud. 2012;53:135-149
• Cho JH, Cho SD, Hu H, et al. The roles of ERK1/2 and p38 MAP kinases in the preventive mechanisms of mushroom Phellinus linteus against the inhibition of gap junctional intercellular communication by hydrogen peroxide. Carcinogenesis. 2002;23(7):1163-1169
• Memorial Sloan Kettering Cancer Center. Phellinus linteus monograph. mskcc.org (accessed February 2026)

Connections

• Compare with Meshima (Phellinus igniarius) — a closely related Hymenochaetaceae species historically confused with P. linteus under the umbrella term “Meshima”; both share beta-glucan immunostimulatory activity and melanin content, but P. linteus has stronger clinical support through the Korean Mesima pharmaceutical program and a more extensively characterized hispolon pharmacology
• Compare with Sang Huang (Sanghuangporus sanghuang) — the mulberry-tree-specific species recently separated from the broader Phellinus complex; the three species (P. linteus, P. igniarius, S. sanghuang) were historically conflated under “Sang Huang” / “Sang Hwang” / “Meshima,” and disambiguating them is essential for accurate evidence interpretation
• Compare with Turkey Tail (Trametes versicolor) — the closest comparator in terms of clinical validation as a cancer adjunctive immunotherapy; Turkey Tail PSK holds pharmaceutical approval in Japan, paralleling Mesima’s approval in South Korea, and both represent the benchmark for mushroom-derived biological response modifiers with regulatory recognition
• Compare with Reishi (Ganoderma lucidum) — shares the dual polysaccharide + polyphenol pharmacological architecture, though reishi emphasizes ganoderic acid triterpenoids while P. linteus emphasizes hispolon styrylpyrones; reishi has broader clinical evidence (Cochrane review) but P. linteus has formal pharmaceutical approval
• The hispolon pharmacology is P. linteus’s most distinctive contribution: direct NF-kB-mediated antitumor activity combined with immunomodulatory polysaccharides provides a dual mechanism (direct cytotoxicity + immune enhancement) within a single organism, a feature shared to a lesser degree with Chaga (betulinic acid + beta-glucans)
• The selective Th1-enhancing/Th2-suppressing profile distinguishes P. linteus from most other medicinal mushrooms, whose beta-glucans tend to be broadly immunostimulatory; this selectivity makes it theoretically advantageous for patients with concurrent immune deficiency and atopic/allergic conditions